Abstract 7491: ctDNA liquid biopsy result among gynecologic cancer patients: Does it give additional information

Abstract Objectives: There are many target molecules for precisional cancer therapy Precision diagnosis-based target treatment is believed to be better survival approach compared than conventional treatment. Predictive markers are variant and vast. This study evaluated the initial experience of ctDNA liquid biopsy as a precision tumor marker for gynecologic cancer patients? Methods: we retrospectively identified ovary/endometrial and cervical cancer patients who approved ctDNA test for various purpose. Two methods were used. Guardant 360 and Foundation One Liquid CDx. Results: There were 31 cases. Median age was 60 (46-84). Half of cases were ovarian cancer (17/31 55%). Cervix and endometrial cancer are 12 (39%) and 2 (6%). We found about ten percentages of actional genetic mutation patients (3/31). Two BRCA1 mutation (each patients have variant allele frequency (VAF) percentages are 50. 4, 49. 6). One high bTMB (blood tumor mutational burden) was 21. There was no mutation in 6/31 (19 %). Conclusions: It seems additional supportive information may be acquired through well-established ctDNA liquid biopsy test among this population. Role of ctDNA liquid biopsy test for precision tumor marker should be investigated for future study. Keywords: Liquid biopsy; Precision medicine; Tumor marker Citation Format: Min Kyu Kim. ctDNA liquid biopsy result among gynecologic cancer patients: Does it give additional information abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts) ; 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84 (6Suppl): Abstract nr 7491.